CABLIVI (caplacizumab-yhdp)
AGENTS TO TREAT THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP) · ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA
GENZYME
Drug class
Agents to treat Thrombotic Thrombocytopenic Purpura (TTP)
Agents to treat thrombotic thrombocytopenic purpura (TTP) are an indication-based grouping of therapies rather than a single pharmacologic mechanism of action. Read more about Agents to treat Thrombotic Thrombocytopenic Purpura (TTP)
3 drugs in this class 2 manufacturers
Drugs in Agents to treat Thrombotic Thrombocytopenic Purpura (TTP)
CABLIVI (caplacizumab-yhdp)
AGENTS TO TREAT THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP) · ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA
GENZYME
ADZYNMA (ADAMTS13, recombinant-krhn)
AGENTS TO TREAT THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP) · CONGENITAL THROMBOTIC THROMBOCYTOPENIC PURPURA
Takeda Pharmaceuticals America
Filter & compare in the drug finder →
Opens the drug finder with Agents to treat Thrombotic Thrombocytopenic Purpura (TTP) preselected. Add indication or manufacturer filters there.
Agents to treat thrombotic thrombocytopenic purpura (TTP) are an indication-based grouping of therapies rather than a single pharmacologic mechanism of action.
This therapeutic category encompasses targeted biological agents—most notably anti-von Willebrand factor directed nanobodies that prevent microvascular platelet aggregation, and recombinant ADAMTS13 enzyme replacement products—as well as systemic immunosuppressive agents that suppress anti-ADAMTS13 autoantibodies.
Used alongside therapeutic plasma exchange, these agents are indicated for the management and prevention of acute episodes of immune-mediated and congenital thrombotic thrombocytopenic purpura to alleviate thrombocytopenia, microangiopathic hemolytic anemia, and life-threatening systemic microvascular thrombosis.
-
drugs.com
Agents to treat thrombotic thrombocytopenic purpura (TTP) are an indication-based grouping of therapies rather than a single pharmacologic mechanism of action
-
touchhaematology.com
Agents to treat thrombotic thrombocytopenic purpura (TTP) are an indication-based grouping of therapies rather than a single pharmacologic mechanism of action
-
fda.gov
This therapeutic category encompasses targeted biological agents—most notably anti-von Willebrand factor directed nanobodies that prevent microvascular platelet aggregation, and recombinant ADAMTS13 enzyme replacement products—as well as systemic immunosuppressive agents that suppress anti-ADAMTS13 autoantibodies Used alongside therapeutic plasma exchange, these agents are indicated for the management and prevention of acute episodes of immune-mediated and congenital thrombotic thrombocytopenic ...
-
takeda.com
This therapeutic category encompasses targeted biological agents—most notably anti-von Willebrand factor directed nanobodies that prevent microvascular platelet aggregation, and recombinant ADAMTS13 enzyme replacement products—as well as systemic immunosuppressive agents that suppress anti-ADAMTS13 autoantibodies
-
nih.gov
This therapeutic category encompasses targeted biological agents—most notably anti-von Willebrand factor directed nanobodies that prevent microvascular platelet aggregation, and recombinant ADAMTS13 enzyme replacement products—as well as systemic immunosuppressive agents that suppress anti-ADAMTS13 autoantibodies
-
bleeding.org
Used alongside therapeutic plasma exchange, these agents are indicated for the management and prevention of acute episodes of immune-mediated and congenital thrombotic thrombocytopenic purpura to alleviate thrombocytopenia, microangiopathic hemolytic anemia, and life-threatening systemic microvascular thrombosis
-
nih.gov
Used alongside therapeutic plasma exchange, these agents are indicated for the management and prevention of acute episodes of immune-mediated and congenital thrombotic thrombocytopenic purpura to alleviate thrombocytopenia, microangiopathic hemolytic anemia, and life-threatening systemic microvascular thrombosis
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.